Related Experiment Video

Updated: Aug 14, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

[Efficacy of isosorbide-5-mononitrate retard in patients with stable exertional angina]

A A Demin, E A Aksenova

    Klinicheskaia Meditsina
    |November 11, 2005
    PubMed

    The aim of the study was to evaluate efficiency of isosorbide-5-mononitrate (IMN) retard (40 to 80 mg/day) in 33 patients older than 60 with stable angina pectoris (functional class III-IV). The study shows that IMN is an effective and safe antianginal agent in treatment of patients with stable angina: it decreased the frequency of anginal attacks (from 4.1 +/- 0.34 to 0.8 +/- 0.13 per day, p < 0.0001), and additional nitroglycerin intake (from 2.2 +/- 0.32 to 0.2 +/- 0.05 tablets per day, p < 0.0001); according to the results of 24-hour ECG monitoring, it reduced ST-segment depression (from 2.2 +/- 0.17 to 0.9 +/- 0.09, p < 0.0001), preventing episodes of painful and silent myocardial ischemia (from 3.5 +/- 0.37 to 2.1 +/- 0.31, p < 0.0001); increased life quality as demonstrated by evaluation of physical (from 19.7 +/- 2.2 to 45.7 +/- 2.22, p < 0.0001), and mental (from 30.9 +/- 2.67 to 57.5 +/- 2.67, p < 0.0001) components using MOS-SF 36 questionnaire. Adverse effects of the drug (headache and hypotension) were observed in 6 (16.6%) patients.

    More Related Videos

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

    Published on: February 3, 2021

    Related Concept Videos

    Antianginal Drugs: Nitrates and &#946;-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Angina V: Nursing Management01:20

    Angina V: Nursing Management

    Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...